*EMBARGOED All research presented at the 2022 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm EDT.

Lucas Duits, MD, PhD

Lucas Duits, MD, PhD

Oral 10 – An Objective Spatialomics Test Standardizes Management Decisions With Potential to Improve Health Outcomes for Barrett’s Esophagus Patients

Monday, October 24, 2022 | 10:18 AM – 10:30 AM ET | Location: Hall C2

Author Insight from Lucas Duits, MD, PhD, Amsterdam University Medical Centres

What’s new here and important for clinicians?

A diagnosis of low-grade dysplasia in Barrett’s esophagus warrants expert pathology review to improve risk stratification for development of esophageal adenocarcinoma. However, this pathology review lacks standard criteria, is highly variable and is fraught with logistical challenges.

In this study we performed management decision simulation to compare standard of care management with standard of care management with addition of guidance by an objective risk stratification test called TissueCypher. The current work shows that the TissueCypher Barrett’s Esophagus test improves the likelihood of appropriate management for Barrett’s patients with an initial community-based diagnosis of low-grade dysplasia. Patients who progressed to high-grade dysplasia or esophageal adenocarcinoma were significantly more likely to be offered endoscopic eradication therapy or intensified endoscopic surveillance. Patients who did not progress were significantly more likely to receive endoscopic surveillance in 3-5 years. The TissueCypher Barrett’s Esophagus test strongly decreases the inconsistencies in management decisions for Barrett’s patients with low-grade dysplasia, by reducing the impact of variable pathology review. The TissueCypher Barrett’s Esophagus test can be used to standardize management decisions in Barrett’s patients with low-grade dysplasia. This results in reduced incidence and mortality of esophageal adenocarcinoma and a reduction in the unnecessary use of endoscopic eradication therapy as well as a reduction in the overuse of endoscopic surveillance.

What do patients need to know?

The risk of developing esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia can be objectively determined by analysis of the biopsies with the TissueCypher Barrett’s Esophagus test. A high-risk result by TissueCypher could lead to treatment intervention that prevents development of esophageal adenocarcinoma. Alternatively, a low-risk test result can reduce burdensome and frequent surveillance endoscopies.

” width=

Read the Abstract

Author Contact
Lucas Duits, MD, PhD, Amsterdam University Medical Centres

l.c.duits [at] amsterdamumc.nl

Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.